Summary of Research: Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy. (PubMed, Adv Ther) - Oct 9, 2026 - P3 | "CheckMate 9ER demonstrated a significant overall survival (OS) benefit for first-line cabozantinib plus nivolumab (CaboNivo) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC)...TSE-adjusted counterfactual median OS [95% confidence interval (CI)] was 42.7 (38.4-49.1) months for CaboNivo and 21.3 (18.1-24.9) months for SUN [HR 0.53 (95% CI 0.43-0.65; p < 0.001)]; unadjusted estimates were 46.5 (40.6-53.7) months for CaboNivo and 35.5 (29.2-42.8) months for SUN [HR 0.79 (95% CI 0.65-0.96; p = 0.0196)]. Removing the effect of subsequent therapy increased the estimated OS benefit of CaboNivo versus SUN, reinforcing CaboNivo as a first-line standard of care for aRCC.Trial Registration NCT03141177."
Journal • P3 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|
|
Alessia Ogareva; Camillo Porta; Emma Karim; James Truscott; Marc-Oliver Grimm; Mickael Lothgren; Pragya Shukla; Venediktos Kapetanakis
|